What are the major opportunities in the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market? What are the strategies for the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market?

For detailed insights on the major opportunities and strategies in the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market, Read More

How does the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market relate to the overall economy and other similar markets?

For detailed insights on Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market growth? SWOT analysis of the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market.

For detailed insights on the key dynamics influencing the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs market growth and SWOT analysis of the Glucagon Like Peptide GLP 1 Agonists Weight Loss Drugs industry, Read More

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Global Report 2026 Market Report Infographic Image

Published : February 2026

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026

Name: Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drugs (Semaglutide, Liraglutide, Tirzepatide, Other Drugs), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

• Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market size has reached to $15.5 billion in 2025

• Expected to grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%

• Growth Driver: Rising Prevalence Of Obesity Fueling The Growth Of The Market Due To Increasing Demand For Effective Weight Management Solutions

• Market Trend: Innovative GLP-1Based Therapies Driving Advances In Obesity Treatment

• North America was the largest region in 2025.

What Is Covered Under Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Glucagon-like peptide (GLP)-1 agonists are medications that replicate the action of the GLP-1 hormone to help control blood sugar and reduce appetite. They boost insulin release, delay stomach emptying, and increase feelings of fullness. Initially designed for type 2 diabetes, they are now commonly used for weight management in overweight and obese patients.

The main drugs involved in glucagon-like peptide (GLP)-1 agonists weight loss drugs market are semaglutide, liraglutide, tirzepatide, and other drugs. Semaglutide, marketed as wegovy, is an injectable prescription medication designed to aid weight loss in adults with obesity or overweight conditions accompanied by weight-related health issues. The different routes of administration include parenteral and oral and are distributed through hospital pharmacies, retail pharmacies, and other pharmacies.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Global Report 2026 Market Report bar graph

What Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size and Share 2026?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from $15.5 billion in 2025 to $18.02 billion in 2026 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to rising obesity prevalence, diabetes drug innovation, lifestyle disease burden, early glp-1 diabetes use, healthcare awareness campaigns.

What Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Forecast?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to approval of new glp-1 drugs, expansion of obesity clinics, increased insurance coverage, long-term weight management focus, rising global obesity rates. Major trends in the forecast period include rising demand for pharmacological weight management, increased use of injectable weight loss drugs, growing adoption of glp-1 therapies beyond diabetes, expansion of obesity treatment programs, improved patient adherence to long-term therapy.

Book your 30 minutes free consultation with our research experts

Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmentation

1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs

2) By Route of Administration: Parenteral, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

Subsegments:

1) By Semaglutide: Ozempic, Wegovy, Rybelsus

2) By Liraglutide: Saxenda, Victoza

3) By Tirzepatide: Mounjaro, Zepbound

4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide

What Is The Driver Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The rising prevalence of obesity is expected to propel the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that presents a risk to health. Obesity rates are growing due to unhealthy eating habits where people consume more fast food and sugary drinks, lacking proper nutrition and balance. As the number of individuals affected by obesity and its related complications continues to rise, the demand for effective treatment options is increasing, thereby driving the use of glucagon-like peptide (GLP-1) agonist weight loss drugs for their proven ability to support weight loss and enhance metabolic health. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023. Therefore, the rising prevalence of obesity is driving the growth of glucagon-like peptide (GLP)-1 agonist weight loss drugs market.

Key Players In The Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd

Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends and Insights

Major companies operating in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing innovative obesity treatment solutions to enhance efficacy and improve patient outcomes. Obesity treatment solutions refer to therapies that mimic the GLP-1 hormone to regulate appetite, enhance satiety, and promote weight loss. These drugs help manage obesity by improving metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received US Food and Drug Administration approval for Zepbound, a medication for chronic weight management in adults with obesity or overweight who have related health conditions such as type 2 diabetes or sleep apnea. The drug works by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

In December 2023, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics for $2.7 billion. With this acquisition, Roche gains access to Carmot's pipeline of incretin-based therapies for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868 and GLP-1 receptor agonist CT-996. Carmot Therapeutics Inc. is a US-based biotechnology company that focuses on developing disease-modifying therapies for metabolic diseases, such as obesity and diabetes.

Regional Outlook

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market consists of sales of products such as dulaglutide (trulicity), exenatide (byetta, bydureon), and lixisenatide (adlyxin). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide (glp)-1 agonists weight loss drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$18.02 billion
Revenue Forecast In 2035	$32.87 billion
Growth Rate	CAGR of 16.3% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drugs, Route of Administration, Distribution Channel
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics And Precision Medicine

4.1.2 Artificial Intelligence And Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data And Cybersecurity

4.1.4 Sustainability, Climate Tech And Circular Economy

4.1.5 Industry 4.0 And Intelligent Manufacturing

4.2. Major Trends

4.2.1 Rising Demand For Pharmacological Weight Management

4.2.2 Increased Use Of Injectable Weight Loss Drugs

4.2.3 Growing Adoption Of Glp-1 Therapies Beyond Diabetes

4.2.4 Expansion Of Obesity Treatment Programs

4.2.5 Improved Patient Adherence To Long-Term Therapy

5. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Weight Management Clinics

5.3 Endocrinology Clinics

5.4 Retail Pharmacies

5.5 Online Pharmacies

6. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmentation

9.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Semaglutide, Liraglutide, Tirzepatide, Other Drugs

9.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Parenteral, Oral

9.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

9.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Ozempic, Wegovy, Rybelsus

9.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Saxenda, Victoza

9.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Mounjaro, Zepbound

9.7. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Exenatide, Dulaglutide, Albiglutide, Efpeglenatide

10. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Regional And Country Analysis

10.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

11.1. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

12.1. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

13.1. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

14.1. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

14.2. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

15.1. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

16.1. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

17.1. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

17.2. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

18.1. Taiwan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

18.2. Taiwan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

19.1. South East Asia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

19.2. South East Asia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

20.1. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

20.2. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

21.1. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

22.1. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

23.1. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

24.1. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

25.1. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

26.1. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

26.2. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

27.1. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

28.1. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

28.2. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

29.1. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

29.2. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

30.1. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

30.2. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

31.1. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

31.2. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

32.1. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

33.1. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

33.2. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

34.1. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

34.2. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Regulatory and Investment Landscape

36. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape And Company Profiles

36.1. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Company Profiles

36.3.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Boehringer Ingelheim Overview, Products and Services, Strategy and Financial Analysis

37. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Other Major And Innovative Companies

Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd

38. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

40. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market High Potential Countries, Segments and Strategies

40.1 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Overview Of Key Products - Product Examples

Table 2: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Supply Chain Analysis

Table 4: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Raw Material Providers

Table 5: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Resource Providers

Table 6: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Manufacturers (Suppliers)

Table 7: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Distributors And Channel Partners

Table 8: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Key Technologies & Future Trends

Table 9: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Trends

Table 10: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major End Users

Table 11: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - TAM, US$ Billion, 2025

Table 15: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 97: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Company Scoring Matrix

Table 98: Novo Nordisk A/S Financial Performance

Table 99: Eli Lilly and Company Financial Performance

Table 100: Pfizer Inc. Financial Performance

Table 101: Merck & Co Inc Financial Performance

Table 102: Boehringer Ingelheim Financial Performance

Table 103: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Competitive Benchmarking (In USD Billions)

Table 104: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Competitive Dashboard

Table 105: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 106: Global, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), Segmentation By Drugs, 2025 – 2030

Table 107: Global, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030

Table 108: Global, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

Figure 1: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Overview Of Key Products - Product Examples

Figure 2: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Supply Chain Analysis

Figure 4: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Raw Material Providers

Figure 5: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Resource Providers

Figure 6: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Manufacturers (Suppliers)

Figure 7: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Distributors And Channel Partners

Figure 8: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Key Technologies & Future Trends

Figure 9: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major Trends

Figure 10: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Major End Users

Figure 11: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - TAM, US$ Billion, 2025

Figure 15: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 97: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Company Scoring Matrix

Figure 98: Novo Nordisk A/S Financial Performance

Figure 99: Eli Lilly and Company Financial Performance

Figure 100: Pfizer Inc. Financial Performance

Figure 101: Merck & Co Inc Financial Performance

Figure 102: Boehringer Ingelheim Financial Performance

Figure 103: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Competitive Benchmarking (In USD Billions)

Figure 104: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Competitive Dashboard

Figure 105: Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 106: Global, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), Segmentation By Drugs, 2025 – 2030

Figure 107: Global, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030

Figure 108: Global, Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Glucagon-like Peptide 1 Market Report 2026 - Global Outlook – By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users (Hospitals, Special...

Weight Loss Drugs Market Report 2026 - Global Outlook – By Type (Liquid, Tablets, Capsules), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Weight-Reducing Aid, Fat Absorpt...

Peptide Based Metabolic Disorders Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Liraglutide, Exenatide, Other Drug Type), By Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterol...

Peptide Therapeutics Market Report 2026 - Global Outlook – By Type (Generic, Branded), By Route of Administration (Parenteral, Mucosal, Oral, Transdermal), By Application (Cancer, Cardiovascular Diseases, Central Nervous...

Alpha Glucosidase Inhibitors Market Report 2026 - Global Outlook – By Type (Dumping Syndrome, Type 2 Diabetes), By Drug Class (Acarbose, Miglitol, Voglibose), By Constituent (Glucoamylase, Isomaltase, Maltase, Sucrase), ...

Weight Loss Supplements Market Report 2026 - Global Outlook – By Type (Liquid, Powder, Softgels, Pills, Other Types), By Ingredients (Vitamins And Minerals, Amino Acids, Natural Extracts Or Botanicals), By Distribution (...

Glucaric Acid Market Report 2026 - Global Outlook – By Type (Calcium D-Glucarate, Pure Glucaric Acid, D-Glucaric Acid-1,4-Lactone, Potassium Sodium D-Glucarate, Other Types), By Application (Detergents, Healthcare, Corro...

Frequently Asked Questions

How big is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market was valued at $15.5 billion in 2025, increased to $18.02 billion in 2026, and is projected to reach $32.87 billion by 2030.

What is the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market growth?

The global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market is expected to grow at a CAGR of 16.2% from 2026 to 2035 to reach $32.87 billion by 2035.

Who are the key players in Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

Some Key Players in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market Include, Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd .

What is the anticipated growth trend for the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

Major trend in this market includes: Innovative GLP-1Based Therapies Driving Advances In Obesity Treatment. For further insights on this market. request a sample here

Which region has the most growth potential in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market?

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.